Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow
Profound Medical (NASDAQ:PROF), a commercial-stage medical device company specializing in incision-free tissue ablation therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments. Investors can access the call through registration and listen to the live broadcast on the company's website.
Profound Medical (NASDAQ:PROF), un'azienda di dispositivi medici in fase commerciale specializzata in terapie di ablazione tissutale senza incisioni, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 14 agosto 2025, dopo la chiusura del mercato.
La società terrà una conference call alle 16:30 ET lo stesso giorno, durante la quale la direzione esaminerà i risultati finanziari e discuterà degli sviluppi aziendali. Gli investitori possono accedere alla chiamata tramite registrazione e ascoltare la trasmissione in diretta sul sito web dell'azienda.
Profound Medical (NASDAQ:PROF), una empresa de dispositivos médicos en etapa comercial especializada en terapias de ablación tisular sin incisiones, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el 14 de agosto de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia a las 4:30 p.m. ET el mismo día, donde la gerencia revisará los resultados financieros y discutirá los desarrollos comerciales. Los inversores pueden acceder a la llamada registrándose y escuchar la transmisión en vivo en el sitio web de la empresa.
Profound Medical (NASDAQ:PROF)는 절개 없는 조직 소작 치료를 전문으로 하는 상업 단계 의료기기 회사로, 2025년 8월 14일 2분기 2025년 재무 실적 발표를 시장 마감 후로 예정했습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜을 개최하여 경영진이 재무 실적을 검토하고 사업 현황에 대해 논의할 예정입니다. 투자자들은 등록을 통해 콜에 접속할 수 있으며 회사 웹사이트에서 생중계 방송을 들을 수 있습니다.
Profound Medical (NASDAQ:PROF), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans les thérapies d’ablation tissulaire sans incision, a prévu l’annonce des résultats financiers du deuxième trimestre 2025 pour le 14 août 2025, après la clôture du marché.
L’entreprise organisera une conférence téléphonique à 16h30 (heure de l’Est) le même jour, au cours de laquelle la direction présentera les résultats financiers et discutera des développements commerciaux. Les investisseurs peuvent accéder à l’appel en s’inscrivant et écouter la diffusion en direct sur le site web de l’entreprise.
Profound Medical (NASDAQ:PROF), ein medizinisches Geräteunternehmen in der kommerziellen Phase, das sich auf schnittfreie Gewebeablationstherapien spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 am 14. August 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, bei der das Management die Finanzergebnisse vorstellen und Geschäftsentwicklungen besprechen wird. Investoren können über eine Anmeldung an dem Anruf teilnehmen und die Live-Übertragung auf der Website des Unternehmens verfolgen.
- None.
- None.
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Second Quarter 2025 Results Conference Call Details:
Date: Thursday, August 14, 2025
Time: 4:30 p.m. ET
Live Call Registration: https://register-conf.media-server.com/register/BId85901c392a54415b6f548e3faded51e
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When will Profound Medical (PROF) release Q2 2025 earnings?
What time is Profound Medical's Q2 2025 earnings conference call?
How can investors access Profound Medical's Q2 2025 earnings call?
What does Profound Medical (PROF) company do?
